Pulse Biosciences, Inc. (NASDAQ:PLSE) CEO Sells $871,000.00 in Stock

by · The Markets Daily

Pulse Biosciences, Inc. (NASDAQ:PLSE – Get Free Report) CEO Burke Thomas Barrett sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total transaction of $871,000.00. Following the sale, the chief executive officer now owns 63,172 shares of the company’s stock, valued at approximately $1,100,456.24. This represents a 44.18 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Pulse Biosciences Price Performance

PLSE opened at $17.98 on Friday. Pulse Biosciences, Inc. has a 1 year low of $6.59 and a 1 year high of $22.69. The stock has a fifty day moving average price of $17.91 and a 200 day moving average price of $16.60.

Pulse Biosciences (NASDAQ:PLSE – Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same quarter last year, the company earned ($0.19) earnings per share.

Institutional Investors Weigh In On Pulse Biosciences

A number of large investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. lifted its position in shares of Pulse Biosciences by 193.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock worth $2,598,000 after buying an additional 97,565 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Pulse Biosciences in the 3rd quarter worth approximately $588,000. Creative Planning boosted its position in Pulse Biosciences by 113.9% during the third quarter. Creative Planning now owns 21,910 shares of the company’s stock worth $384,000 after purchasing an additional 11,667 shares during the period. Quest Partners LLC acquired a new position in Pulse Biosciences during the second quarter valued at approximately $91,000. Finally, Bank of New York Mellon Corp raised its position in shares of Pulse Biosciences by 23.4% in the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock valued at $570,000 after purchasing an additional 9,639 shares during the period. 76.95% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a research note on Thursday, December 12th.

Read Our Latest Stock Report on Pulse Biosciences

Pulse Biosciences Company Profile

(Get Free Report)

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

Featured Articles